A phase I study of MGCD 0103 given as a three-times weekly oral dose in patients with advanced solid tumours or non-Hodgkin's lymphoma

Trial Profile

A phase I study of MGCD 0103 given as a three-times weekly oral dose in patients with advanced solid tumours or non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celgene Corporation; MethylGene; Pharmion Corporation
  • Most Recent Events

    • 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
    • 11 Dec 2008 Actual completion date reported as October 2008 by ClinicalTrials.gov.
    • 11 Dec 2008 Status changed from suspended to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top